Table 1 Vaccine candidates for COVID-19 as of February 25, 2021 [191,192,193,194,195,196,197,198,199,200,201,202]
Vaccine name | Organization/Institute(s) | Manufacturer | Comments |
|---|---|---|---|
BNT162b2 | – | Pfizer, BioNTech | mRNA-based vaccine 95% effective after the second dose |
mRNA-1273 | Kaiser Permanente Washington Health Research Institute | Moderna | mRNA-based vaccine 94.1% effective after the second dose |
AZD1222 (Covishield) | University of Oxford The Jenner Institute | AstraZeneca | Chimpanzee adenovirus vaccine vector 62.1% and 90.0% effective in 2 different dosing regimens |
Sputnik V | Gamalaya Research Institute of Epidemiology and Microbiology | Gamalaya Research Institute of Epidemiology and Microbiology | Recombinant adenovirus vaccine 91.6% effective after the first dose |
CoronaVac | Sinovac Research and Development Co. Ltd | Sinovac | Formalin-inactivated and alum-adjuvanted vaccine |
Ad5-nCoV | Tongji Hospital in Wuhan, China | CanSino Biologics | Recombinant vaccine incorporating adenovirus type 5 vector |
JNJ-78436735 | Janssen Vaccines and Prevention B.V | Janssen Vaccines and Prevention B.V | Non-replicating viral vector vaccine |
BBIBP-CoRV | Henan Provincial Center for Disease Control and Prevention | Beijing Institute of Biological Products, and Sinopharm | Inactivated vaccine |
EpiVacCorona | Federal Budgetary Research Institution State Research Center of Virology and Biotechnology | – | Peptide vaccine |
Covaxin | – | Bharat Biotech, National Institute of Virology | Inactivated vaccine |
CoviVac | – | Chumakov Federal Scientific Center for Research and Development of Immune and Biological Products | Inactivated vaccine |
– | Wuhan Institute of Biological Products | Sinopharm | Inactivated vaccine |